Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1973 1
1974 1
1975 1
1976 4
1977 4
1978 3
1979 5
1980 1
1981 2
1982 4
1983 5
1984 3
1985 2
1986 1
1987 4
1988 5
1990 1
1993 1
1994 2
1995 3
1996 2
1997 5
1998 4
1999 2
2000 3
2001 3
2002 3
2003 2
2004 1
2005 5
2006 2
2007 7
2008 2
2009 4
2010 1
2011 9
2012 8
2013 5
2014 3
2015 1
2016 1
2017 5
2018 4
2019 1
2020 5
2021 3
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 11966629

140 results

Results by year

Filters applied: . Clear all
Page 1
Hormonal predictors of prostate cancer.
Sofikerim M, Eskicorapci S, Oruç O, Ozen H. Sofikerim M, et al. Urol Int. 2007;79(1):13-8. doi: 10.1159/000102906. Urol Int. 2007. PMID: 17627161
Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB, Migliorini F, Petrozziello A, Sava T, Romano M, Caruso B, Cocco C, Ghimenton C, Zecchinini Antoniolli S, Lacola V, Rubilotta E, Monaco C, Comunale L. Porcaro AB, et al. Urol Int. 2012;88(2):150-7. doi: 10.1159/000334596. Epub 2011 Dec 23. Urol Int. 2012. PMID: 22205171
[Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
Bantis A, Zissimopoulos A, Athanasiadou P, Gonidi M, Agelonidou E, Strataki A, Matthaios D, Tsartsarakis A. Bantis A, et al. Hell J Nucl Med. 2007 Jan-Apr;10(1):56-61. Hell J Nucl Med. 2007. PMID: 17450256 Clinical Trial. Greek, Modern.
Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer and subsequent cluster selection of the patient population undergoing standard radical prostatectomy.
Porcaro AB, Migliorini F, Petrozziello A, Sava T, Romano M, Caruso B, Cocco C, Ghimenton C, Zecchinini Antoniolli S, Lacola V, Rubilotta E, Monaco C, Comunale L. Porcaro AB, et al. Urol Int. 2013;90(1):45-55. doi: 10.1159/000343430. Epub 2012 Nov 2. Urol Int. 2013. PMID: 23128438
140 results